Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2338282
Max Phase: Preclinical
Molecular Formula: C36H37F3N4O5
Molecular Weight: 662.71
Molecule Type: Small molecule
Associated Items:
ID: ALA2338282
Max Phase: Preclinical
Molecular Formula: C36H37F3N4O5
Molecular Weight: 662.71
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cc2c(cc1OC)[C@@H]1[C@@H]3Cc4cc(OC)c(OC)cc4[C@H](CNC(=O)/C=C/c4ccc(C(F)(F)F)cc4)N3[C@@H](C#N)[C@H](C2)N1C
Standard InChI: InChI=1S/C36H37F3N4O5/c1-42-26-12-22-15-31(46-3)33(48-5)17-25(22)35(42)27-13-21-14-30(45-2)32(47-4)16-24(21)29(43(27)28(26)18-40)19-41-34(44)11-8-20-6-9-23(10-7-20)36(37,38)39/h6-11,14-17,26-29,35H,12-13,19H2,1-5H3,(H,41,44)/b11-8+/t26-,27-,28-,29-,35+/m0/s1
Standard InChI Key: ZOKSOCAUZYTGFS-QCIFZFOVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 662.71 | Molecular Weight (Monoisotopic): 662.2716 | AlogP: 5.34 | #Rotatable Bonds: 8 |
Polar Surface Area: 96.29 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 4.73 | CX LogP: 5.18 | CX LogD: 5.18 |
Aromatic Rings: 3 | Heavy Atoms: 48 | QED Weighted: 0.32 | Np Likeness Score: 0.35 |
1. Guo J, Dong W, Liu W, Yan Z, Wang N, Liu Z.. (2013) Synthesis and cytotoxicity of 3-aryl acrylic amide derivatives of the simplified saframycin-ecteinascidin skeleton prepared from L-dopa., 62 [PMID:23434640] [10.1016/j.ejmech.2013.01.033] |
Source(1):